β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy.
Gunter Johannes SturmSereina Annik HerzogWerner AbererTeresa Alfaya AriasDarío Antolín-AmérigoPatrizia BonadonnaElisa BoniAndrzej BozekMarta ChełmińskaBarbara ErnstNina FrelihRadoslaw GawlikAslı GelincikThomas HawranekWolfram HoetzeneckerAránzazu Jiménez BlancoKarolina KitaReşat KendirlinanKosnik MitjaKarin LaipoldRoland LangFrancesco MarchiMarina MauroMarita Nittner-MarszalskaIwona Poziomkowska-GęsickaValerio PravettoniDonatella PreziosiOliviero QuerciaNorbert ReiderMarta Rosiek-BiegusBerta Ruiz-LeonChristoph SchrautzerPilar SerranoAytül SinBetül Ayşe SinJohanna StoevesandtAxel TrautmannMartina VachováLisa Arzt-GradwohlPublished in: Allergy (2021)
This trial provides robust evidence that taking β-blockers or ACEI does neither increase the frequency of systemic AE during VIT nor aggravate SSR. Moreover, results suggest that these drugs do not impair effectiveness of VIT. (Funded by Medical University of Graz, Austria; Clinicaltrials.gov number, NCT04269629).